SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a major partnership with OpenAI, which involves AMD stock warrants and a commitment to deploy AMD's Instinct GPUs, seen as a challenge to Nvidia's dominance in AI. The community is buzzing about the potential for AMD to become a trillion-dollar company, though some express concern about the speed of the stock's recent surge and potential dilution. This move is viewed as a significant validation of AMD's technology in the rapidly growing AI sector.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending amid significant volume and price fluctuations, with community discussions focused on potential breakouts and a tug-of-war between bullish and bearish sentiments. Some investors are optimistic about the company's prospects given recent institutional investments and a new foundry, while others express concerns about dilution and valuation. The broader context involves the speculative nature of the quantum computing sector, with debates about its long-term viability and comparisons to established tech companies.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to high volatility and a massive volume spike following the expiration of a lock-up period, leading to significant price swings and heavy discussion around potential short squeezes. Community members are actively debating the stock's future, with some expressing bullish sentiment based on institutional buying and oversold conditions, while others remain cautious due to its past performance and the potential for further insider selling. The elevated borrowing fee rate for short positions is also a key talking point, fueling speculation about a possible squeeze.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as investors digest concerns from the Bank of England about an AI bubble and its potential impact on global financial security. Community discussions also revolve around whether VTI can still be a 'millionaire-maker' for long-term investors and monitor reports on earnings and price target updates for its top holdings. Recent news includes analysis of Tesla and AMD's performance, which heavily influences VTI's trajectory given their significant weighting in the ETF.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amidst both bullish and bearish sentiment, with some traders eyeing a potential move towards higher price targets while others express concerns about valuation and an impending correction. Discussions revolve around the company's technology, potential government contracts, and comparisons to other quantum computing stocks. The emergence of a 2x short ETF, QBTZ, has also fueled debate, with some interpreting it as a sign of an imminent downturn.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the stock price surges, fueled by speculation around potential government funding, NOAA approvals, and growing excitement in the metals sector. The community is actively discussing the possibility of a short squeeze and the potential for new partnerships, with some setting ambitious price targets for the near future. Discussions also include the company's potential to address critical mineral supply chain concerns.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community buzzes about potential catalysts, including exchange listings, the upcoming SuperApp release, and partnerships within the sports industry following a recent sponsorship debut. Social media engagement and staking rewards are also key talking points, with many comparing ZBCN's potential to early XRP. Despite some skepticism, bullish sentiment prevails as holders anticipate significant growth and real-world adoption.

TOSHI

TOSHI is trending as community members rally around the project, expressing excitement about its potential and encouraging each other to support its growth. The community is actively discussing its market cap, potential listings on major platforms like Robinhood and Binance, and comparing it to other meme coins like DOGE and SHIB. Speculation around exchange listings and anticipation of significant gains appear to be fueling the current interest.

Turn Therapeutics Inc

Turn Therapeutics ($TTRX) is trending as it appears on Franky's Watchlist, a source of potential setups and trade ideas. The community is actively discussing the stock's potential, with some viewing it as a high-risk, high-reward play.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as community members discuss its potential to reach $200 amid news of US approval for chip exports to the UAE. Bullish sentiment is fueled by ongoing AI compute demand and potential investments in xAI, while some traders debate whether the stock is overvalued and ripe for a correction. Discussions also include comparisons to AMD and its recent partnership with OpenAI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Galafold Drive Amicus' Growth Through the Rest of 2025?

Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's How Alvotech is Expanding its Portfolio Beyond Immunology

ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.

Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?

ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.

J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?

J&J shares gain 17.7% in three months, adding $63B to its market cap. Technical and pipeline momentum fuel investor interest.

Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth

Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.

ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.

Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced on Thursday that the U.S. Food and Drug Administration has approved a generic version of the Liraglutide injection known as Saxenda.Liraglutide Injection is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated to reduce excess body weight and maintain weight reduction long-term in adults as well as pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. The drug is to be used in combination with a reduced-calorie diet and increased physical activity.“With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tevapharm.com/news-and-media/latest-news/teva-announces-fda-approval-and-launch-of-generic-saxenda-liraglutide-injection--first-generic-glp-1-/">said</a> Ernie Richardsen, Head of U.S. Commercial Generics at Teva. He added that it marks an important addition to the company’s generics portfolio.Saxenda, Novo Nordisk’s older obesity drug, had annual sales of $165 million as of June 2025, the company said. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TEVA">TEVA stock</a> trended within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_9_52_29_AM_png_ba7ec14e95.webp" alt="TEVA's Sentiment Meter and Message Volume as of 9:52 a.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>TEVA's Sentiment Meter and Message Volume as of 9:52 a.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise that the stock is not trading higher despite the approval.<stembedurl>https://stocktwits.com/RemitTekram/message/626845403</stembedurl>Another user sounded skeptical, saying that the stock would probably end the day in the red despite “explosive news.”<stembedurl>https://stocktwits.com/NoTradeAnymore/message/626842741</stembedurl>In the second quarter, Teva recorded revenue of $4.2 billion and adjusted and diluted earnings per share of $0.66. Generics product revenues in the U.S., however, fell 6% to $961 million, due to lower revenues from Lenalidomide capsules, the generic version of Revlimid, and Liraglutide injection 1.8mg, an authorized generic of Victoza, primarily driven by increased competition.TEVA stock is down 19% this year and approximately 3% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lakeshore-biopharma-receives-revised-proposal-to-acquire-company/chs6JRRRdmm">LakeShore Biopharma Receives Revised Proposal To Acquire Company</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A very overweight woman with swollen feet stands on a scale that reads 145.1 kilograms. Overweight and obesity are increasing at a rapid pace worldwide. Photo: Pia Bayer/dpa (Photo by Pia Bayer/picture alliance via Getty Images)

This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More

The company’s U.S. affiliate announced that the U.S. Food and Drug Administration has approved a generic version of Liraglutide injection, known as Saxenda.

Equity

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.67	--	--	N/A
Q2 '25	$0.62	$0.66	7.03%	BEAT
Q1 '25	$0.46	$0.52	12.43%	BEAT
Q4 '24	$0.71	$0.71	0.38%	BEAT
Q3 '24	$0.66	$0.69	4.38%	BEAT

TEVA
Teva- Pharmaceutical Industries Ltd. - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest TEVA News

TEVA Teva- Pharmaceutical Industries Ltd. - ADR